RxDoctor Payments Data

Larry Elj

Psychiatric/Mental Health · Grand Rapids, MNNPI 1376150235

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 24 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 11 manufacturers, the largest accounting for just 20.5% — the pattern of someone who eats at a lot of different presentations.

$373in general payments, 2019–2025

Across 24 payments — averaging $15.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$76
  • Alkermes, Inc.$59
  • Neurocrine Biosciences, Inc.$46
  • Vanda Pharmaceuticals Inc.$45
  • AbbVie$41
  • Supernus Pharmaceuticals, Inc.$32
  • plus $73 from 5 others

What the payments were for

  • Food & beverage$373100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$373 in reported general payments places this provider in the 85th percentile of 407 psychiatric/mental health providers in Minnesota.

See all psychiatric/mental health providers in Minnesota

Medicare billing

Part B allowed, 2024
$32,296
Medicare patients
44
Services billed
385

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl52$77,393
SpravatoEsketamine Hcl37$40,242
RexultiBrexpiprazole29$21,270
SuboxoneBuprenorphine Hcl/Naloxone Hcl11$11,871
Ziprasidone Hcl40$3,932
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl34$3,755
Clozapine92$3,066
Aripiprazole72$2,574
Memantine Hcl12$2,163
Quetiapine Fumarate ErQuetiapine Fumarate24$1,740
Propranolol Hcl80$1,345
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine53$1,305
Risperidone92$1,222
Buspirone Hcl93$1,149
Duloxetine Hcl84$1,147

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$41$77,39352 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 407 psychiatric/mental health providers in Minnesota.

Other psychiatric/mental health in Grand Rapids

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →